Articles

AI-Driven Drug Discovery Partnership: Merck and Mayo Clinic Lead Innovation

Merck and the Mayo Clinic have launched a groundbreaking AI-driven drug discovery partnership. This collaboration aims to revolutionize pharmaceutical research by integrating artificial intelligence and clinical expertise to speed up new drug development.

Pharma Supercomputer: Eli Lilly and NVIDIA’s AI-Powered Breakthrough

Eli Lilly and NVIDIA have partnered to build the pharmaceutical industry's most powerful supercomputer. This AI-driven innovation aims to accelerate drug discovery and development, enhancing computational research capabilities globally.

Merck Mayo Clinic AI Partnership: Advancing Drug Discovery

Merck and the Mayo Clinic have joined forces to leverage AI in accelerating drug discovery and development. This partnership combines Merck's expertise with Mayo Clinic's research capabilities to transform pharmaceutical innovation.

NMPA Approval ADCs Lung Cancer: Trends & Clinical Insights 2025

This article delves into the latest NMPA-approved antibody-drug conjugates (ADCs) for lung cancer, examining trends and clinical insights shaping 2025.

CAR-T Cell Therapy Japan: Regulatory Insights & Clinical Trial Landscape

This article delves into CAR-T cell therapy in Japan, highlighting regulatory frameworks and the evolving clinical trial landscape for hematologic malignancies.

Biosimilar Landscape in Japan: Impact of PMDA Guideline Updates 2025

This article delves into the impact of the 2025 PMDA guideline updates on the biosimilar landscape in Japan, highlighting significant drugs and their indications.

NMPA Accelerated Approval Oncology: Impact on Innovative Drug Market Access in China

This article examines the NMPA's accelerated approval process and its significant influence on the market access of innovative oncology drugs in China.

SAKIGAKE Designation Japan: What You Need to Know About PMDA's Expedited Pathway

Learn about the SAKIGAKE Designation in Japan, a fast-track pathway by PMDA for innovative drugs, enhancing access for patients with unmet medical needs.

Biosimilar Market Growth Japan: Impact of PMDA's 2024 Regulatory Update

The PMDA's 2024 regulatory update is set to significantly influence the growth of the biosimilar market in Japan, particularly for drugs like adalimumab.

Chinese-Developed ADCs Integration: Clinical Impact & Regulatory Advances in APAC

This article delves into the integration of Chinese-developed antibody-drug conjugates (ADCs) and their significant clinical and regulatory advancements in the APAC region.

Biosimilar Landscape Japan: Impact of PMDA Updates & SAKIGAKE Designations

This article delves into the impact of recent PMDA updates and SAKIGAKE designations on the biosimilar market in Japan, particularly for Trastuzumab in breast cancer treatment.

APAC KRAS Inhibitors: Elisrasib’s Promise in Advanced NSCLC

Elisrasib emerges as a promising KRAS inhibitor, revolutionizing treatment options for advanced NSCLC in the APAC region.

PMDA SAKIGAKE Designation: Accelerating Novel Cardiovascular Drug Approvals

Explore the impact of PMDA SAKIGAKE Designation on speeding up the approval process for groundbreaking cardiovascular drugs, including CardioX.

Radioligand Therapies for Prostate Cancer: Market Access and Clinical Insights in APAC

This article delves into the landscape of radioligand therapies for prostate cancer, focusing on market access and clinical insights across the APAC region.

NMPA Priority Review Pathway: What You Need to Know About Innovative Drug Approvals

Learn how the NMPA Priority Review Pathway accelerates innovative drug approvals, enhancing access to cutting-edge therapies for patients with critical conditions.

Biosimilar Landscape in Japan: Impact of PMDA Updates & SAKIGAKE 2024

This article delves into the impact of recent PMDA updates and the SAKIGAKE initiative on the biosimilar market in Japan, highlighting implications for drugs like adalimumab.

Australian Biotech Solid Tumor CAR-T: What You Need to Know

Explore the advancements in Australian Biotech's CAR-T therapy for solid tumors, offering new hope for patients battling cancer with innovative treatment options.

Biosimilar Market Growth Japan: Impact of PMDA's 2024 Interchangeability Guidelines

This article examines how the PMDA's 2024 interchangeability guidelines will influence the growth of the biosimilar market in Japan, focusing on drugs like Adalimumab.

NMPA Approval Oncology Drugs: Accelerated & Conditional Pathways Explained

This article delves into the NMPA's accelerated and conditional pathways for oncology drugs, highlighting their significance in expediting approvals for critical treatments.

HSA Clinical Trial Modernization: Singapore's New Framework for CITDs

Singapore's innovative framework for Clinical Investigation of Therapeutic Devices (CITDs) aims to modernize clinical trials, enhancing drug safety and efficacy.